8-K Featured Impact 8/10 Commercial Agreement

$TEM · Tempus AI, Inc.

November 18, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Tempus AI filed an 8-K disclosing a Fifth Amendment to its Master Services Agreement with AstraZeneca, effective Jan 1, 2027. The amendment establishes a new five-year financial commitment period through Dec 31, 2031, with AstraZeneca committing $200M in aggregate fees ($40M annual target, $32M annual minimum). AstraZeneca retains the right to terminate for convenience but must pay any shortfall of the $200M commitment if it terminates before fulfilling it.

  • AstraZeneca committed $200M in aggregate fees over the Renewal Term.
  • Annual target spend is $40M; annual minimum is $32M per calendar year.
  • Term extends through Dec 31, 2031, with possible extension to 2032 if commitment unmet.
  • AstraZeneca retains termination-for-convenience rights but owes shortfall if it exits early.
  • Amendment effective Jan 1, 2027, extending the original Nov 17, 2021 MSA.

Extended-hours last trade $63.99, +0.88% vs regular close but -1.19% vs price at filing; regular session down 2.05%. Modest positive reaction to a revenue-commitment extension.

A $200M committed revenue stream from a major pharma partner strengthens Tempus's multi-year revenue visibility.

Extends a multi-year strategic collaborator relationship in AI-driven precision medicine, reinforcing recurring revenue visibility for Tempus.

AstraZeneca can terminate for convenience at any time, though it would owe any shortfall of the $200M commitment.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →